Daily Ards Research Analysis
Analyzed 10 papers and selected 3 impactful papers.
Summary
Analyzed 10 papers and selected 3 impactful articles.
Selected Articles
1. Tetrahedral DNA Nanostructure-Based Biomimetic Nanovesicles Attenuate Sepsis-Associated ARDS by Suppressing Glycolysis via the BMAL1/PFKFB3 Axis.
This study demonstrates that activating BMAL1 in alveolar macrophages suppresses PFKFB3-driven glycolysis and inflammation, and that an inhaled biomimetic nanovesicle (RM@TNT) can deliver a BMAL1 agonist to the lung to achieve this effect. In SA-ARDS mice, RM@TNT reduced lung injury and edema and significantly improved survival, establishing a targeted immunometabolic therapy.
Impact: It integrates mechanistic insight (BMAL1/PFKFB3 axis) with a translatable delivery platform that improved survival in vivo, pointing to a new therapeutic class for ARDS.
Clinical Implications: While preclinical, the work supports inhaled, macrophage-targeted immunometabolic modulation as a feasible ARDS strategy and motivates early-phase trials and companion biomarker development.
Key Findings
- BMAL1 directly represses PFKFB3 to inhibit glycolysis and M1 polarization in alveolar macrophages.
- A biomimetic, ROS-responsive nanovesicle (RM@TNT) delivers a BMAL1 agonist (nobiletin) to AMs after inhalation.
- RM@TNT attenuated lung inflammation, injury, and edema and significantly improved survival in SA-ARDS mice.
Methodological Strengths
- Mechanistic validation linking BMAL1 to PFKFB3 repression with functional metabolic and inflammatory readouts.
- In vivo efficacy with survival improvement using a targeted, inhaled delivery system.
Limitations
- Findings are in murine SA-ARDS and may not fully recapitulate human ARDS heterogeneity.
- Safety, biodistribution, and manufacturability of the complex nanoplatform were not clinically evaluated.
Future Directions: Advance to GLP toxicology and large-animal inhalation studies; define pharmacodynamics and identify biomarkers of BMAL1 activation to enable phase I trials.
Sepsis-associated acute respiratory distress syndrome (SA-ARDS) is a life-threatening complication characterized by excessive pulmonary inflammation and pulmonary edema, lacking effective treatments. This study identifies the transcription factor BMAL1 in alveolar macrophages (AMs) as a key therapeutic target. Mechanistically, BMAL1 represses the expression of the glycolytic enzyme PFKFB3 by binding to the Pfkfb3 promoter, thereby inhibiting glycolysis, M1 polarization of AMs, and the generation of pro-inflammatory cytokines and reactive oxygen species (ROS). Based on this regulatory mechanism, a biomimetic nanoplatform, RM@TNT, is engineered for precise SA-ARDS therapy. Fabricated by hybridizing AM membrane-derived nanovesicles with ROS-responsive liposomes, the nanoplatform encapsulates tetrahedral DNA nanostructures (TNT) preloaded with nobiletin (Nob, a BMAL1 agonist) and Tuftsin (an AM-targeting peptide). Following inhalation, the AM membrane tropism of RM@TNT ensures prolonged pulmonary retention, prompting targeted TNT release within the ROS-rich pathological microenvironment. Tuftsin then precisely delivers TNT to AMs, where Nob is intracellularly released to activate BMAL1. This activation upregulates the BMAL1/PFKFB3 axis, suppressing AM glycolysis, inflammation, and oxidative stress. Treatment with RM@TNT resulted in significantly attenuated lung inflammation, injury, and edema, along with markedly improved survival in SA-ARDS mice. Collectively, this multimodal, targeted metabolic reprogramming approach is a highly promising therapeutic strategy for SA-ARDS.
2. The PPARβ/Delta-Induced Mesenchymal Stromal Cell Secretome Has Cytoprotective Effects via ANGPTL4 in a Pre-Clinical Model of Acute Lung Inflammation.
PPARβ/δ activation in human MSCs produces an ANGPTL4-high secretome that enhances epithelial repair and endothelial barrier integrity. Licensing MSCs with ARDS patient serum further augments therapeutic effects in an LPS-induced acute lung inflammation model, and anti-ANGPTL4 neutralization confirms mechanism.
Impact: Identifies ANGPTL4 as a mechanistic effector of MSC therapy and demonstrates a practical ex vivo licensing strategy to enhance secretome potency relevant to ARDS.
Clinical Implications: Supports development of cell-free MSC secretome therapies and rational preconditioning (licensing) to enhance efficacy for ARDS-like lung injury.
Key Findings
- PPARβ/δ-agonized hBM-MSC secretome increased pro-reparative effects via ANGPTL4 in CALU-3 epithelial cells.
- ANGPTL4-high MSC secretome improved endothelial barrier integrity in LPS-induced ALI mice.
- Licensing MSCs with ARDS patient serum further enhanced therapeutic effects; anti-ANGPTL4 antibody abrogated benefits.
Methodological Strengths
- Integrated in vitro and in vivo evaluation with mechanistic confirmation via antibody neutralization.
- Clinically relevant licensing using human ARDS patient serum to enhance translatability.
Limitations
- ALI LPS model may not capture full complexity of human ARDS.
- Secretome composition variability and manufacturing standardization were not fully addressed.
Future Directions: Define GMP-compatible licensing protocols, quantify ANGPTL4 thresholds for efficacy, and assess safety/efficacy in large-animal lung injury models.
Human bone marrow-derived mesenchymal stromal cells (hBM-MSCs) are known to exert immunomodulatory and pro-reparative effects in vivo. This makes hBM-MSCs an enticing therapeutic candidate for inflammatory diseases, such as acute respiratory distress syndrome (ARDS). The ARDS microenvironment is complex and contains an abundance of free fatty acids (FFAs), which are known to differentially impact MSC functionality. PPARβ/δ is a ubiquitously expressed nuclear receptor that is activated in response to FFA-binding. PPARβ/δ has been shown to impact the therapeutic efficacy of mouse MSCs. This study sought to investigate the impact of PPARβ/δ-modulation on human MSC functionality in vitro and in vivo. hBM-MSCs were exposed to a synthetic PPARβ/δ agonist/antagonist in the presence or absence of ARDS patient serum and the immunomodulatory and pro-reparative capacity of the MSC secretome was investigated using in vitro assays and a pre-clinical model of LPS-induced acute lung inflammation (ALI). Our results highlighted enhanced pro-reparative capacity of PPARβ/δ-agonized hBM-MSCs secretome in CALU-3 lung epithelial cells, mediated by MSC derived angiopoietin-like 4 (ANGPTL4). PPARβ/δ-induced ANGPTL4-high MSC secretome facilitated enhanced endothelial barrier integrity in the lungs of ALI mice. Therapeutic effects of PPARβ/δ-agonized hBM-MSCs secretome were further enhanced by licensing MSCs with human ARDS patient serum. ARDS-licensed PPARβ/δ-induced ANGPTL4-high MSC secretome had reduced clinical score and weight loss. The role ANGPL4 in these protective effects was confirmed using an anti-ANGPTL4 antibody. These findings conclude that the MSC secretome therapeutic effects can be enhanced both in vitro and in vivo through licensing strategies that upregulate the angiogenic factor ANGPTL4.
3. Effects of antifungal treatment in COVID-19-associated pulmonary aspergillosis: A European multicenter cohort study.
In 259 CAPA patients across European ICUs, antifungal therapy—predominantly azoles—was associated with markedly lower 60-day mortality (HR 0.31; IPTW-weighted HR 0.28). Age, immunosuppression, and remdesivir use were linked to higher mortality, supporting active CAPA screening and early targeted treatment.
Impact: Provides multicenter, propensity-weighted evidence that antifungal therapy improves survival in CAPA, addressing an urgent therapeutic gap in critically ill COVID-19 patients.
Clinical Implications: Encourages routine CAPA screening in ventilated COVID-19 patients and timely initiation of azole therapy when probable/proven CAPA is diagnosed, while awaiting RCTs.
Key Findings
- Among 259 CAPA patients, antifungal treatment was associated with lower 60-day mortality (HR 0.31; IPTW-weighted HR 0.28).
- Age, immunosuppressive therapy, and remdesivir administration were independently associated with higher mortality.
- Baseline characteristics were similar between treated and untreated groups; most treated patients received azoles.
Methodological Strengths
- Multicenter European cohort with standardized survival analyses.
- Use of propensity score-based inverse probability of treatment weighting to mitigate confounding.
Limitations
- Observational design cannot establish causality; residual confounding may persist.
- Heterogeneity of antifungal regimens and supportive care across centers.
Future Directions: Randomized controlled trials to confirm causal benefit, optimize antifungal choice/duration, and integrate early CAPA screening pathways.
BACKGROUND: The management of COVID-19-associated invasive aspergillosis (CAPA) is still debated while cases continue to occur, and more and more frequently in vulnerable populations, stressing the importance of obtaining data on the treatment of this disease. Only small cohort studies and case-reports have yet discussed this essential issue and data obtained are insufficient to conclude with confidence. RESEARCH QUESTION: Is antifungal treatment associated with lower 60-day mortality in patients with probable or proven CAPA? STUDY DESIGN AND METHODS: We assessed the association of antifungal treatment with 60-day mortality for probable/proven CAPA cases from a French multicenter study and all consecutive CAPA cases (post-2020) from intensive care units of five major European centers. Patients were compared according to antifungal treatment. Survival analysis was conducted using Cox regression analysis and inverse probability of treatment weighting based on a propensity score. RESULTS: In total, 259 CAPA patients were included, 237 (91.5%) receiving antifungals for CAPA of whom 215 (90.7%) received azole antifungal drugs. Baseline characteristics were similar between patients who received antifungals and those who did not. Age (HR 1.02, 95%CI:1.00-1.04, p=0.048), immunosuppressive treatment (HR 2.08, 95%CI:1.12-3.41, p<0.001], and remdesivir administration (HR 1.96, 95%CI:1.12-3.41, p=0.018) were independently associated with increased 60-day mortality by Cox regression analysis in the raw population. Male sex (HR 0.61, 95%CI:0.40-0.95, p=0.024) and antifungal treatment (HR 0.31, 95%CI:0.17-0.59, p<0.001) were associated with lower 60-day mortality. Cox-weighted regression showed lower 60-day mortality for patients receiving antifungals (weighted HR 0.28 [95%CI:0.13-0.58], p<0.001. INTERPRETATION: We observed that antifungal treatment was associated with lower 60-day mortality in CAPA patients. The high mortality rate observed in CAPA in immunocompromised patients and improved outcome for treated patients should encourage clinicians to actively screen for CAPA to enable rapid diagnosis and targeted treatment.